Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction Magnetic Resonance Imaging (MRI)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- conformity index
研究概览
简要总结
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
详细描述
To prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.The related factors causing this change are discussed.The relationship between changes and patient survival was analyzed.A predictive model was established to provide individualized adaptive radiotherapy for patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old;
- •High-grade glioma was confirmed by pathology after surgery;
- •ECOG score 0-2 points;
- •Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
- •Baseline data available.
排除标准
- •The pathological diagnosis is not clear;
- •No synchronous chemotherapy/adjuvant chemotherapy < 6 cycles;
- •There are other malignant tumors;
- •Previously radiotherapy to the head;
- •Interruption of radiotherapy for more than 5 days;
- •Failure to collect baseline data.
结局指标
主要结局
conformity index
时间窗: up to 2 weeks
CI: conformity index. Dosimetric change
Homogeneity index
时间窗: up to 2 weeks
HI: Homogeneity index. Dosimetric change
Anatomic change
时间窗: up to 2 weeks
Dmax Volume
次要结局
- progression-free survival (PFS)(assessed up to 12 months)
研究者
Ping Ai
Clinical Professor
West China Hospital